24MAY

CEPI rescues Moderna H5N1 vaccine trial

2 min read

16:06UTC

CEPI committed $54.3m to keep Moderna's Phase 3 mRNA H5N1 vaccine trial alive after the US health department scrapped its funding.

← Back to Ebola triples, response misfires Jump to analysis ↓

ScienceDeveloping

Key takeaway

CEPI is now funding the leading bird-flu vaccine trial that US federal money abandoned mid-stream.

The Coalition for Epidemic Preparedness Innovations (CEPI) committed $54.3 million to keep alive Moderna's Phase 3 trial of its messenger-RNA (mRNA) H5N1 vaccine after the US Department of Health and Human Services scrapped the federal funding ¹. First participants were dosed on 21 April , and the candidate, mRNA-1018, is the furthest any mRNA H5N1 vaccine has reached ². H5N1 is the avian influenza strain whose spread through dairy cattle and poultry has kept pandemic planners watching.

The rescue is the same retreat-and-backstop pattern visible at the US border and in the thinned-out Ituri response: a US withdrawal from a pandemic-preparedness commitment, absorbed by a multilateral body. CEPI did not fund this trial originally; it stepped into a gap created by a policy decision, which leaves the world's leading bird-flu vaccine candidate dependent on whoever is willing to cover the cost after the largest single funder leaves.

Deep Analysis

In plain English

H5N1 is the bird flu strain that has been spreading in US dairy cattle since 2024. Scientists have long worried that if it mutates to spread easily between people, it could cause a severe pandemic. Moderna, a US vaccine company, developed an mRNA-based H5N1 vaccine candidate called mRNA-1018 using the same technology platform as the Covid-19 vaccines. It is now in Phase 3, the large-scale human trial that tests whether a vaccine is safe and effective before it can be approved. CEPI, the Coalition for Epidemic Preparedness Innovations (a global partnership funded by governments and charities), committed $54.3 million to keep the trial running after the US government's health department pulled its funding. First participants were dosed on 21 April 2026. This trial matters because if H5N1 did cause a human pandemic, an already-tested mRNA vaccine could be adapted and produced far faster than a traditional egg-based vaccine.

Source Landscape

This story draws on neutral-leaning sources

Consensus view: CEPI's 100 Days Mission framework, which aims to have a vaccine in Phase 3 trial within 100 days of a declared pandemic threat, is being tested in real time by the mRNA-1018 commitment: CEPI's $54.3 million fills the gap left by HHS withdrawing US government funding, but the dependency is now on a single Coalition funder rather than the distributed public-private architecture that produced COVID-19 vaccines at speed.

First dosing on 21 April and Phase 3 continuation to completion represents the furthest any mRNA H5N1 candidate has reached.

Counter-view: The Pasteur Network's regulatory capacity programme, which CEPI expanded via a 21 April 2026 partnership , argued that the mRNA-1018 trial's value is contingent on regulatory capacity in potential pandemic-affected countries: if H5N1 achieves efficient human-to-human transmission in Southeast Asia or Latin America, those countries' regulatory agencies would need expedited review pathways to authorise the vaccine for emergency use.

Those pathways still do not exist in most middle-income countries, regardless of how fast CEPI can manufacture doses.

Key tension: Whether a Phase 3 trial result obtained under CEPI funding, without US government co-ownership, can be leveraged into rapid FDA Emergency Use Authorisation and simultaneous WHO Emergency Use Listing: the two regulatory gates that would determine actual deployment speed in a pandemic.

Sources:Coalition for Epidemic Preparedness Innovations

Mentions:H5N1 →United States →Phase 3 →Pasteur Network →Coalition →Washington →World Health Organization →Moderna →CEPI →

First Reported In

Update #4 · Ebola triples, response misfires

Coalition for Epidemic Preparedness Innovations· 24 May 2026

Read original →

Causes and effects

Caused by

Moderna begins Phase 3 H5N1 mRNA trial

CEPI's $54.3m commitment rescues the Moderna Phase 3 trial that began dosing on 22 April after CEPI's original announcement.

Occurred 22 Apr 2026

Read story →

This Event

CEPI rescues Moderna H5N1 vaccine trial

A multilateral coalition is now financing the furthest-advanced bird-flu vaccine that Washington walked away from.

Different Perspectives

Chinese health authorities

China reported three human H9N2 cases to WHO between 10 and 16 July: two four-year-olds recovered, a 44-year-old man remains in intensive care, the first severity signal in a cluster that has produced 173 cases and 2 deaths globally since 2015. The subtype is distinct from the H5N1 series this topic otherwise tracks.

US public health authorities

CIDRAP and Dr Andrew Racine, president of the American Academy of Pediatrics, call 2026's 2,318 confirmed measles cases by 24 July the worst year since 1991's 2,126. Zero deaths against three in 2025 and a 7% hospitalisation rate, down from 11%, show record case counts have not brought record severity.

CEPI

CEPI put an rVSV-platform vaccine candidate specific to Bundibugyo ebolavirus into trial-production on 31 July, developed by Hilleman Laboratories with MSD manufacturing and IAVI's reference virus, funded up to $8.5m. Eleven weeks into the third-largest Ebola outbreak on record, this is the first species-matched candidate; the licensed vaccine covers only Zaire ebolavirus.

Médecins Sans Frontières

MSF reports sexual-violence care in Ituri is almost non-existent, with 7 of 14 health centres closed or relocated by fighting, as Panzi Hospital logs 646 new survivors in six months, an 85% rise. Withdrawn US funding for post-exposure prophylaxis has left clinics across three provinces without PEP kits for months, a crisis running alongside Ebola, not caused by it.

DRC health workers at Elikya Ebola Treatment Centre

Staff at DRC's Elikya Ebola Treatment Centre walked out on 25 July over unpaid wages, the second such action after Rwampara, while unconfirmed suspects occupy up to 64% of the country's isolation beds awaiting lab results. Workers are absorbing a response that has grown faster than its payroll and its labs.

Uganda's Ministry of Health

Uganda's ministry says it discharged its last confirmed patient on 16 June, completed every contact's 21-day follow-up, and declared the country Ebola-free on 28 July, exactly 42 days later. It names Hon. Dr Chris Baryomunsi, Minister of Health, as overseeing a 20-case, 2-death outbreak it now considers closed.